Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Amid those worries, I've been tracking prices every day for 11 key products likely to be hit by tariff-induced price increases, and the answer I've come to so far is this: Not so much, at least ...

The deadline for the start of Trump's heaviest tariffs has been delayed until next month as Amazon's Prime Day sales bonanza kicks off to take the edge off price hikes.